###begin article-title 0
Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 175 178 <span type="species:ncbi:9606">men</span>
###xml 183 188 <span type="species:ncbi:9606">woman</span>
Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC). ChRCC is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman. Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2. Prognosis of ChRCC is better than in other types of RCC. Five- and 10-year disease free survival (DFS) for ChRCC was 83.9% and 77.9%, respectively. Expression of immunohistological markers: cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 could be potentially helpful in diagnosis of different subtypes of RCC. From all conventional RCC, CD 117 was detected (overexpression) in membrane of cells ChRCC.
###end p 2
###begin p 3
Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase inhibitors like: imatinib, dasatinib, nilotinib. The potential targets for other kinase inhibitors (sunitinib and sorafenib) in ChRCC seem to be VEGFR and PDGFR. On the basis for formulating research hypotheses which should be verified by prospective studies.
###end p 3
###begin title 4
Epidemiology
###end title 4
###begin p 5
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 159 162 <span type="species:ncbi:9606">men</span>
###xml 172 177 <span type="species:ncbi:9606">women</span>
Renal cell carcinoma (RCC) is rather a rare neoplasm (in Poland about 3% of all tumors). According to the most recent National Cancer Register in Poland, 2150 men and 1501 women were diagnosed with renal cancer in 2004 [1].
###end p 5
###begin p 6
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
Approximately 200,000 new cases of RCC are diagnosed annually worldwide, while the number of deaths caused by RCC approaches 100,000. Cure can be obtained in 70-90% of patients in the TNM stage I, in 55-70% of patients in stage II, in 20-30% of patients in stage III, and in less than 10% in stage IV [2].
###end p 6
###begin p 7
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
The 2004 World Health Organization (WHO) classification of RCC recognized several subtypes of RCC. Most common subtypes are: clear cell RCC (70%), papillary RCC (10-15%), chromophobe RCC (4-6%), collecting duct carcinoma (about 1%) and unclassified RCC (4-5%) [3,4].
###end p 7
###begin p 8
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 226 227 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 108 111 <span type="species:ncbi:9606">men</span>
###xml 116 121 <span type="species:ncbi:9606">woman</span>
Chromophobe RCC (ChRCC) is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman [5]. 86% of ChRCCs are diagnosed in stage 1 or 2 [3]. Renal vein invasion is seen in about 5% of cases [5].
###end p 8
###begin p 9
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 79 80 79 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Incidence of metastatic disease in chromophobe renal cell carcinoma is 6-7% [6,7].
###end p 9
###begin p 10
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
In summary of 28 cases based on 7 reports, most common metastatic sites were liver (39%) and lung (36%) [6].
###end p 10
###begin title 11
Pathology
###end title 11
###begin p 12
###xml 68 69 68 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Chromophobe RCC was first described in patients by Thoenes in 1985 [8].
###end p 12
###begin p 13
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Macroscopically, ChRCC is a solitary, circumscribed, and not capsulated mass with a homogeneous light brown cut surface. The median tumor size of ChRCC is 6.0 cm, and it is larger than that of other subtypes [7].
###end p 13
###begin p 14
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
Microscopically, it contains of large, polygonal cells with prominent cell membrane [5]. Cytoplasm is pale and resistant to staining with hematoxylin and eosin. ChRCC cells have irregular nuclei with perinuclear clear halo. The tumor blood vessels have thick walls and are eccentrically hyalinized [3].
###end p 14
###begin p 15
###xml 739 740 739 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
Chromophobe RCC is a heterogeneous group including classic type, eosinophilic type and mixed type. Eosinophilic variant (containing greater than 80% eosinophilic cells) has areas similar to renal oncocytomas (nested, alveolar or sheetlike architecture with eosinophilic granularity, perinuclear clearing, peripheral accentuation of cytoplasm) and it is often bilateral (11%) and multifocal (22%). Classic type of chromophobe RCC (containing greater than 80% pale cells) is associated with necrosis or sarcomatoid change. It has alveolar or sheetlike architecture and cytoplasm with flocculent "soap-bubble" appearance. Chromophobe RCCs with mixed histology have variable architecture (containing admixture of pale and eosinophilic cells) [6].
###end p 15
###begin p 16
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
Microscopic tumor necrosis and sarcomatoid change are known to be aggressive with a high potential for distant metastases [6].
###end p 16
###begin p 17
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
One of the diagnostic criteria of ChRCC is Hale colloidal iron [5], another are intracytoplasmatic microvesicles between 250-400 nm in diameter [9] (Figure 1- Chromophobe renal cell carcinoma, HE, 200x; Figure 2 - Positive reaction showing the presence of colloidal iron in cytoplasm of ChRCC, 400x).
###end p 17
###begin p 18
Chromophobe renal cell carcinoma, HE, 200x.
###end p 18
###begin p 19
Positive reaction showing the presence of colloidal iron in cytoplasm of ChRCC, 400x.
###end p 19
###begin p 20
They can be demonstrated by electron microscopy, which is not used routinely in diagnosis of chromophobe RCC.
###end p 20
###begin p 21
The main diagnostic criteria of chromophobe RCC is morphology coupled with characteristic immunophenotype (diffuse CK7, and KIT positivity).
###end p 21
###begin p 22
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 496 497 496 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Variable expression patterns of cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 and parvalbumin can be potentially helpful in diagnosis of different subtypes of RCC. Vimentin was reported positive in 0-21% of ChRCC, CD10 in 0-33% of ChRCC, CK7 in 60-100% of ChRCC, CK8 in 50% of ChRCC, CK18 in 100% of ChRCC, CK19 in 33% of ChRCC, CK20 in 12.5% of ChRCC, EMA 75-100% of ChRCC and parvalbumin 100% of ChRCC. Sometimes ChRCC can be mistaken for renal oncocytoma [10,11] (Table 1).
###end p 22
###begin p 23
Expression of immunohistological markers of ChRCC
###end p 23
###begin title 24
Clinical and Histomorphological Features
###end title 24
###begin p 25
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 325 326 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Prognosis in ChRCC is better than in other types of RCC. Five- and 10-year DFS for chromophobe RCC was 83.9% and 77.9%, respectively [12]. The median time from nephrectomy to metastasis detection, and from metastasis detection to death were twice as long for ChRCC than for other subtypes of RCC (papillary, clear cell RCC) [7].
###end p 25
###begin p 26
###xml 44 53 44 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p &lt; 0.001</italic>
###xml 78 87 78 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.019</italic>
###xml 102 111 102 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.025</italic>
###xml 137 148 137 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = &lt; 0.001</italic>
###xml 174 183 174 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.012</italic>
###xml 205 214 205 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.020</italic>
###xml 263 272 263 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p &lt; 0.001</italic>
###xml 435 444 435 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.025</italic>
###xml 488 497 488 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.013</italic>
###xml 546 555 546 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.020</italic>
###xml 579 580 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
In univariate analysis: sarcomatoid change (p < 0.001), microscopic necrosis (p = 0.019), tumor size (p = 0.025), pT stage (3.4 vs. 1.2; p = < 0.001), broad alveolar growth (p = 0.012), vascular invasion (p = 0.020), and Fuhrman nuclear grade (grade 4 vs.3 vs 2; p < 0.001) were associated with aggressive ChRCC behavior. Independent predictors (Multivariable Cox Regression) of aggressive ChRCC included: pT stage (pT 3.4 vs. pT 1.2; p = 0.025, relative hazard 3.4), sarcomatoid change (p = 0.013, relative hazard 4.7) and microscopic necrosis (p = 0.020, relative hazard 3.5) [6]. Other factors like: age, sex, histologic subtyping by clear, eosinophilic or mixed cell types, tubulocystic pattern, degenerate or symplastic atypia were not predictors of chromophobe RCC behavior.
###end p 26
###begin p 27
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
The patients with aggressive phenotype of chromophobe RCC may be candidates for adjuvant therapies as they become available [6].
###end p 27
###begin p 28
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
ChRCCs are hyperechogenic in ultrasound examination, CT imaging or MRI demonstrate homogeneous enhancement. A spoke-wheel pattern of contrast enhancement is characteristic for ChRCC and for onkocytoma [13]. Most of ChRCCs are sporadic, but sometimes they are associated with BHD (Birt-Hogg-Dube) syndrome [14].
###end p 28
###begin title 29
Genetic Syndrome associated with chromophobe RCC
###end title 29
###begin p 30
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
BHD syndrome is an autosomal dominant disorder that includes: benign skin tumor (skin tags, fibrofolliculomas), renal epithelial neoplasms (ChRCC, oncocytoma) and spontaneous pneumothorax. Renal tumors are often multifocal and bilateral. BHD gene encodes potential tumor suppressor protein - folliculin on 17p11 [15].
###end p 30
###begin p 31
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
ChRCCs is characterized by length polymorphism such as loss of chromosomal material involving chromosomes: 1, 2, 3p, 6, 10, 13, 17p, 17q and 21 [16,17]. It may be helpful in distinguishing between clear, papillary and chromophobe subtypes of RCC.
###end p 31
###begin title 32
Expression of CD117 (KIT)
###end title 32
###begin p 33
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
KIT (CD117) is a type III receptor tyrosine kinase that plays a role in intracellular signal transduction in several cell types. It regulates apoptosis, cell differentiation, proliferation, chemotaxis, and adhesion. Pathologic activation of KIT through gain-of-function mutations leads to neoplasia of KIT-dependent and KIT-positive cell types in different systems: Cajal cells - gastrointestinal stromal tumors (GISTs), myeloid cells - myeloid leukemia. In addition, many tumors have positive KIT immunoreactivity: small cells carcinomas, adenoid cystic carcinoma, chromophobe, thymic and sometimes ovarian and breast carcinomas [18].
###end p 33
###begin p 34
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 121 125 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KIT </italic>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
In normal tissue of kidney KIT showed weak immunoreactivity only in the cytoplasm of distal tubules [19]. From all RCCs, KIT gene product was detected (overexpression) in membrane of cells ChRCC (88-100%) [19,20]. This is in agreement with histogenetic origin of chromophobe RCC from distal tubules.
###end p 34
###begin p 35
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
KIT expression in classic variant is more often than eosinophilic variant (82% vs. 67%) [21].
###end p 35
###begin p 36
Thus, immunohistochemical detection of KIT expression appears to be useful in diagnosis and treatment of ChRCC.
###end p 36
###begin p 37
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 356 362 356 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 387 393 387 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 468 476 <span type="species:ncbi:9606">patients</span>
Yamazaki et al. reported upregulation of c-kit gene expression in ChRCCs. The mechanism for the overexpression of KIT in ChRCC is unknown. They suggested that the KIT signal pathway in ChRCCs could be activated in an autocrine way [19]. In summary 70 cases, based on 4 reports investigators were unable to detect activating mutations within exon 17 of the c-kit gene [19-22]. Absence of c-kit mutation could be argue for potential effectiveness of imatinib therapy in patients with metastatic ChRCCs.
###end p 37
###begin title 38
Potential targeted therapy for advanced ChRCC
###end title 38
###begin p 39
Now we have three potentially active and targeted agents against CD 117: imatinib, dasatinib and nilotinib.
###end p 39
###begin title 40
Imatinib
###end title 40
###begin p 41
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
as KIT tyrosine kinase inhibitor (TKI) is an accepted treatment of chronic eosinophilic leukemia, hypereosinophilic syndrome, chronic myeloid leukemia, myelodysplastic/myeloproliferate syndrome, acute lymphoblastic leukemia, dermatofibrosarcoma protuberans, gastrointestinal stromal tumors [18]. The targets for imatinib include: BCR/ABL, CD 117, PDGFRA (platelet-derived growth factor receptor) [23] and also DDR1 (discoidin domain receptor 1), NQO2 (quinone reductase QR2) [24,25].
###end p 41
###begin title 42
Dasatinib
###end title 42
###begin p 43
###xml 201 209 201 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
is a second-line multikinase (besides BCR/ABL kinase) inhibitor. Dasatinib is used in patients with chronic myeloid leukemia or acute lymphoblastic leukemia with resistance or intolerance of imatinib. In vitro, it has approximately 325-fold greater potency than imatinib in inhibition of BCR/ABL kinase [26]. In phase II trial, dasatinib increased response rates by > 2-fold versus high-dose of imatinib. The targets for dasatinib include: BCR/ABL, CD 117, PDGFRA, DDR1, DDR2, Src family kinases and ephrin receptor kinases [24,27].
###end p 43
###begin title 44
Nilotinib
###end title 44
###begin p 45
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
is the result of modifications to the imatinib molecule [28,29]. Nilotinib like imatinib, inhibits BCR/ABL, CD 117, PDGFRA, NQO2, DDR1 [24,25,29]. Nilotinib also inhibits CSF-1R (colony-stimulating factor-1 receptor) [30] and EphB4 (ephrin receptor) [31]. Nilotinib was 43-60 times more potent than imatinib in cell lines (KBM5, KBM7) [32].
###end p 45
###begin p 46
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
A phase II clinical trial confirmed activity of nilotinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia [33] (Table 2).
###end p 46
###begin p 47
Targets for Imatinib, Dasatinib and Nilotinib
###end p 47
###begin p 48
We realize that this treatment hypothesis is controversial. Up to now, we have not found cases of successful treatment in the literature. But we think, that prospective trials with these agents in ChRCC should clarify their use in the future.
###end p 48
###begin p 49
###xml 128 138 128 138 <bold xmlns:xlink="http://www.w3.org/1999/xlink">sorafenib </bold>
###xml 142 152 142 152 <bold xmlns:xlink="http://www.w3.org/1999/xlink">sunitinib </bold>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
Other interesting therapies for advanced ChRCC may include therapies used in advanced clear cell renal carcinoma (CCRCC). Both, sorafenib and sunitinib showed clinical activity in randomized clinical trials in treatment metastatic CCRCC [34,35]. These are tyrosine kinases inhibitors including vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) [36,37].
###end p 49
###begin p 50
###xml 342 346 334 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VHL </italic>
###xml 417 419 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
VEGF and PDGF are markers of angiogenesis which plays an essential role in tumor growth and metastatization. Overexpression VEGF and PDGF in RCCs is associated with defective von Hippel-Lindau (VHL) protein. It can induce the expression of the genes involving in angiogenesis through the hypoxia-inducible factor 1alpha (HIF-1alpha) pathway. VHL is inactivated in up to 80% of sporadic cases of clear-cell carcinoma [38].
###end p 50
###begin p 51
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
ChRCC can be associated with high serum levels of VEGF, making VEGF-targeted therapy an attractive therapeutic option [39].
###end p 51
###begin p 52
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
In biochemical and cellular tests both agents inhibit CD 117. They seem to be next potential targeted therapy for advanced ChRCC [37].
###end p 52
###begin p 53
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Choueiri et al. confirmed, that sunitinib and sorafenib are active agents in metastatic ChRCC: 75% of patients had stable disease (SD) more than 3 months and 25% had partial response (PR) [37] Table 3.
###end p 53
###begin p 54
Activity Sorafenib and Sunitynib in ChRCC
###end p 54
###begin title 55
Conclusion
###end title 55
###begin p 56
Currently, we do not have any effective treatment for the metastatic disease apart from surgical procedures. Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase inhibitors like: imatinib, dasatinib, nilotinib. The potential targets for other kinase inhibitors (sunitinib and sorafenib) in ChRCC seem to be VEGFR and PDGFR. In conclusion, these observations are the basis for formulating research hypotheses which should be verified in prospective studies.
###end p 56
###begin title 57
Competing interests
###end title 57
###begin p 58
The authors declare that they have no competing interests.
###end p 58
###begin title 59
Authors' contributions
###end title 59
###begin p 60
RS, LB, MM participated in the sequence alignment and drafted the manuscript. BG was responsible for pathomorphology. RS, CS was responsible for coordination. All authors read and approved the final manuscript.
###end p 60
###begin title 61
Acknowledgements
###end title 61
###begin p 62
Special thanks for Professor W. Kozlowski, The Head of Department of Pathomorphology, Military Institute of Health Services in Warsaw.
###end p 62
###begin article-title 63
Nowotwory zlosliwe w Polsce w 2004 roku
###end article-title 63
###begin article-title 64
Nowotwory ukladu moczowo-plciowego
###end article-title 64
###begin article-title 65
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma
###end article-title 65
###begin article-title 66
Common and uncommon Histologic Subtype of Renal Cell Carcinoma: Imaging Spectrum with Pathologic Correlation
###end article-title 66
###begin article-title 67
Chromophobe Renal Cell Carcinoma: Histomorphologic Characteristics and Evaluation of Conventional Pathologic prognostic Parameters in 145 Cases
###end article-title 67
###begin article-title 68
Effect of Papillary and Chromophobe Cell Type on Disease-Free Survival After Nephrectomy for Renal Cell Carcinoma
###end article-title 68
###begin article-title 69
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human chromophobe cell renal carcinoma
###end article-title 69
###begin article-title 70
Chromophobe Renal Cell Carcinoma With Extensive Calcification and Ossification
###end article-title 70
###begin article-title 71
Distribution of cytokeratins and Vimentin in adult renal neoplasms and normal renal tissue
###end article-title 71
###begin article-title 72
Parvalbumin is constantly expressed in Chromophobe Renal Carcinoma
###end article-title 72
###begin article-title 73
Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience
###end article-title 73
###begin article-title 74
Spoke-wheel-like enhancement as an important imaging finding of chromophobe cell renal carcinoma: carcinoma retrospective analysis on computed tomography and magnetic resonance imaging studies
###end article-title 74
###begin article-title 75
Molecular genetics of familial renal cell carcinoma syndromes
###end article-title 75
###begin article-title 76
Genetic basis of kidney cancer: a model for developing molecular-targeted therapies
###end article-title 76
###begin article-title 77
Application of molecular diagnostic techniques to renal epithelial neoplasms
###end article-title 77
###begin article-title 78
###xml 49 54 <span type="species:ncbi:9606">human</span>
Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinoma
###end article-title 78
###begin article-title 79
KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation
###end article-title 79
###begin article-title 80
Overexpression of KIT in chromophobe renal cell carcinoma
###end article-title 80
###begin article-title 81
A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas
###end article-title 81
###begin article-title 82
Expression of KIT (CD 117) in renal cell carcinoma and renal oncocytoma
###end article-title 82
###begin article-title 83
Overexpression of KIT (CD 117) in chromophobe renal cell carcinoma and renal oncocytoma
###end article-title 83
###begin article-title 84
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Correlation of target kinase genotype with clinical activity of imatinib mesylate in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+) [abstract]
###end article-title 84
###begin article-title 85
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
###end article-title 85
###begin article-title 86
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib
###end article-title 86
###begin article-title 87
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
###end article-title 87
###begin article-title 88
Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL
###end article-title 88
###begin article-title 89
Nilotinib
###end article-title 89
###begin article-title 90
Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis
###end article-title 90
###begin article-title 91
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
###end article-title 91
###begin article-title 92
###xml 59 68 59 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
AMN107, a Novel Aminopyrfimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia
###end article-title 92
###begin article-title 93
###xml 99 107 <span type="species:ncbi:9606">patients</span>
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
###end article-title 93
###begin article-title 94
Sunitynib versus interferon alfa in metastatic renal cell carcinoma
###end article-title 94
###begin article-title 95
Sorafenib in advanced renal-cell carcinoma
###end article-title 95
###begin article-title 96
In vivo antitumor activity of SU1 a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derive d growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
###end article-title 96
###begin article-title 97
Efficacy of Sunitynib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma
###end article-title 97
###begin article-title 98
Renal-cell carcinoma
###end article-title 98
###begin article-title 99
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Serum levels of vascular endothelial growth factor VEGF) and endostatin in renal cell carcinoma patients compared to a control group
###end article-title 99

